cyrilzakka/clinical-trials huggingface dataset:
Outcomes of Fracture Odontoid Management

This study aims to evaluate the long-term outcomes of treating patients with odontoid fractures admitted to the Trauma Unit of Assiut University Hospital.

study focuses on assessing the long-term results of treatment for patients diagnosed with odontoid fractures. These fractures involve the odontoid process of the second cervical vertebra and can be serious due to their potential impact on spinal stability and neurological function. The study is conducted within the Trauma Unit of Assiut University Hospital, indicating that it involves patients who have been admitted for acute care following such injuries. The long-term outcomes likely include factors such as recovery rates, complications, and the effectiveness of different treatment modalities.

The study population consists of patients admitted to the Trauma Unit of Assiut University Hospital with diagnosed odontoid fractures. This population likely includes individuals of various ages and backgrounds who have experienced trauma leading to this specific type of fracture. The study may focus on patients who have undergone different treatment strategies, such as surgical intervention or conservative management, to assess the effectiveness and outcomes of these approaches over time. The demographic characteristics of the population could include age, gender, cause of injury, and pre-existing health conditions, which might influence treatment outcomes.

Eligibility Criteria:
Inclusion Criteria:

* All patients with odontoid fractures presenting to Assiut University Hospital - Department of Orthopaedic and Trauma Surgery who have completed a minimum of 2 year follow up regardless of age, mechanism of injury, neurological status or type of treatment applied.

Exclusion Criteria:

* • Patients who are not available for two year follow-up

  * Patients who refuse to participate in the study
Measurement and Treatment of Back Pain

The aim of this study was to evaluate the clinical aspects and to investigate the therapeutic effects of combined therapy with laser on back pain.

Dysfunctions of the musculoskeletal system are related to physiological, kinesiological and biomechanical factors that result in pain, paresthesia, inflammation, heaviness, fatigue and compression of peripheral nerves. Clinical aspects related to back pain were investigated. For treatment, photobiomodulation can be performed with laser equipment that emits red and infrared light, which promotes analgesic and anti-inflammatory effects. Mechanical stimulus can be combined with laser to improve therapeutical effects. In this context, the laser was combined with ultrasound, negative pressure and positive pressure to treat back pain.

Eligibility Criteria:
Inclusion Criteria:

* Volunteers (female and male)
* Aged between 20 and 60 years
* Who had medical referral for pain complaint in low back

Exclusion Criteria:

* Psychiatric illnesses
* Endocrinopathies
* Heart diseases
* Neurological diseases
* Osteoporosis
* Cancer
* Analgesic, anti-inflammatory or muscle relaxant drugs in the last four weeks
Transversus Abdominis Plane Block Plus Quadratus Lumborum Block or Retrolaminar Block of Multiple Injections for Postoperative Analgesia Following Laparoscopic Colorectal Surgery

Our hypothesis was that transversus abdominis plane block plus retrolaminar block would reduce postoperative sufentanil consumption and provide superior analgesia compared with transversus abdominis plane block plus quadratus lumborum block for laparoscopic colorectal surgery.


Eligibility Criteria:
Inclusion Criteria:

* American Society of Anesthesiologists (ASA) physical status I-II class
* Colorectal cancer patients
* 18 and 80 years old
* Elective laparoscopic colorectal surgery

Exclusion Criteria:

* serious complications associated with other systems:
* severe cardiac insufficiency
* renal failure
* hepatic encephalopathy
* infection in the block injection area
* coagulopathy
* a known allergy to local anesthetics
* a previous history of tranquilizer or opioid abuse,
* body mass index (BMI) greater than 30 kg/m2 or less than 18 kg/m2,
* inability to cooperate with the assessment of visual analogue scale (VAS) pain scores
* refusal to participate in the study
An Evaluation of Pentoxifylline in HIV-Positive Persons With Symptomatic HIV Infection and a Karnofsky Score > 40 Percent and < 100 Percent

PRIMARY: To determine whether pentoxifylline changes the self-reported measures of quality of life status, using measures of scores from double-blinded drug withdrawal and drug restart periods.

SECONDARY: To measure the changes in monthly CD4 counts, fasting serum triglyceride levels, and weight; to assess the safety of pentoxifylline in HIV-infected persons.


Eligibility Criteria:
Inclusion Criteria

Concurrent Medication:

Allowed:

* Stable antiretroviral therapy.
* Maintenance medication for opportunistic infection.

Patients must have:

HIV positivity.

NOTE:

* Patients on an antiretroviral must have received it for at least 2 months and have no currently perceived need to change or add to the regimen for the next 3 months.

Prior Medication:

Allowed:

* Antiviral therapy (provided patient has been on such therapy for at least 2 months at study entry and dose is stable).

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms and conditions are excluded:

* Evidence of active opportunistic infection or malignancy requiring high-dose systemic chemotherapy (only patients who are 30 days from a diagnosis of an opportunistic infection and on appropriate maintenance medication are allowed).
* Known significant intolerance or hypersensitivity to theophylline, theobromine (chocolate), or caffeine, for reasons other than dyspepsia.
* Inability to swallow tablets (gastric feeding tubes are allowed).
* Active bleeding disorder or major bleeding source, including peptic ulcer or gastritis.
* Any symptoms suggestive of concurrent illness that are not attributable to overall impairment by HIV or are not diagnosable based on the available evidence.
* Not willing to comply with visit schedule and study procedures.

Concurrent Medication:

Excluded:

* Concurrent use of the anticoagulant warfarin (Coumadin) and heparin.

Prior Medication:

Excluded:

* Treatment with biologic response modifiers (e.g., interferon, interleukin) within 14 days prior to study entry.

Prior Treatment:

Excluded:

* Major surgery within 30 days of study entry.
Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel

The purpose of this study is to demonstrate equivalent efficacy of GP2015 and Enbrel® in patients with moderate to severe chronic plaque-type psoriasis with respect to PASI 75 response rate at Week 12.

The purpose of this confirmatory safety and efficacy study (GP15-302) was to demonstrate equivalence in efficacy and similarity in safety and immunogenicity of GP2015 and Enbrel (EU-authorized) in patients with moderate to severe chronic plaque-type psoriasis and to evaluate the effects of repeated switching between GP2015 and Enbrel on efficacy, overall safety, and immunogenicity. Since only EU-authorized Enbrel was utilized in this study, the use of the term "Enbrel" throughout this report describes EU-authorized Enbrel only.

Eligibility Criteria:
Inclusion Criteria:

* Men or women at least 18 years of age at time of screening
* Chronic plaque-type psoriasis diagnosed for at least 6 months before baseline
* Moderate to severe psoriasis as defined at baseline by:

  * PASI score of 10 or greater and,
  * Investigator´s Global Assessment score of 3 or greater (based on a scale of 0 - 4) and,
  * Body Surface Area affected by plaque-type psoriasis of 10% or greater
* Chronic plaque-type psoriasis patients who have previously received phototherapy or systemic psoriasis therapy at least once or who are candidates for such therapies in the opinion of the investigator.

Exclusion Criteria:

* Forms of psoriasis other than chronic plaque-type
* Drug-induced psoriasis
* Ongoing use of prohibited treatments
* Previous exposure to etanercept
* Active ongoing inflammatory diseases other than psoriasis that might confound the evaluation of the benefit of treatment with etanercept

Other In-/Exclusion criteria may apply
Assement of the Morphological Characteristics of the Hips and Correlating Them With the Pathology Found

The investigators' objective is the anatomical analysis of hips studied through MRI, assessing their morphological characteristics and correlating them with the pathology found.

A retrospective search was performed using a database of consecutive reports of 137 adults pelvis MRI examinations obtained at MRI center in Zaragoza.

In all the images the investigators are going to measure the ischiofemoral space, quadratus femoris space, cervicodiaphysal angle and femoral version angle. The investigators evaluated different qualitative changes in the signal intensity of the quadratus femoris muscle as normal, edema, fatty infiltration or atrophy, and of the gluteus muscles as tendinopathy or atrophy, too.

The investigators' objective is the anatomical analysis of hips studied through MRI, assessing their morphological characteristics and correlating them with the pathology found.

A retrospective search was performed using a database of consecutive reports of 137 adults pelvis MRI examinations obtained at MRI center in Zaragoza.

The investigators create a protocol for a retrospective review study, with the aim of analysis all the recorded MRI findings during this time. The criteria for patient inclusion were: Age \> 18 years old, who had realised a pelvis MRI for any cause at MRI Center. Exclusion criteria included age \< 18 years old, inadequate imaging quality, medical history likely to affect pelvic and hip morphometry: pelvic oncological disease, infection or inflammatory arthritis, postsurgical change disruptions, soft tissue abnormality, avascular necrosis, or pelvic and hip fracture.

In all the images the investigators are going to measure the ischiofemoral space, quadratus femoris space, cervicodiaphysal angle and femoral version angle. The investigators evaluated different qualitative changes in the signal intensity of the quadratus femoris muscle as normal, edema, fatty infiltration or atrophy, and of the gluteus muscles as tendinopathy or atrophy, too.

Eligibility Criteria:
Inclusion Criteria:

* Age \> 18 years old

Exclusion Criteria:

* Age \< 18 years old
* Inadequate imaging quality
* Medical history likely to affect pelvic and hip morphometry: pelvic oncological disease, infection or inflammatory arthritis, postsurgical change disruptions, soft tissue abnormality, avascular necrosis, or pelvic and hip fracture.
SMS: Substrate Modification Study in Patients Getting an Implantable Cardioverter Defibrillator (ICD)

The present standard of care for the management of unstable ventricular tachycardia (VT) in the setting of chronic coronary artery disease is the placement of an implantable cardioverter defibrillator (ICD) after the initial episode, and radiofrequency ablation and/or antiarrhythmic medication in the event of recurrences causing frequent ICD interventions.

The primary purpose of this randomized study is the assessment of recurrences of unstable VT in patients who undergo ICD implantation plus substrate ablation after the initial episode compared to patients who only undergo ICD implantation. Thus the primary purpose is an improvement in the quality of life. A decrease in mortality is not a primary purpose of this study.


Eligibility Criteria:
Inclusion Criteria:

* Coronary artery disease documented by coronary angiography. For the purpose of this study, coronary artery disease will be defined as the presence of a 50% or more diameter stenosis of the left main or of a 75% or more diameter stenosis of the left anterior descending, circumflex or right coronary arteries, or the history of a surgical or percutaneous revascularization procedure.
* Left ventricular ejection fraction \< 40% as estimated by echocardiography or contrast ventriculography within the previous 30 days.
* Clinical unstable VT without reversible factors (acute ischemia or antiarrhythmic medications as defined below). Unstable VT can have one of the following clinical presentations:

  * Hypotensive VT without major neurologic dysfunction;
  * Syncope; or
  * Cardiac arrest.

Exclusion Criteria:

* Age \< 18 years or \> 80 years
* Protruding left ventricular (LV) thrombus on pre-ablation echocardiogram
* Acute myocardial infarction within the preceding 2 months
* Class IV New York Heart Association (NYHA) heart failure
* Valvular heart disease or mechanical heart valve precluding access to the left ventricle
* Unstable angina
* Cardiac surgery within the past 2 months
* Serum creatinine \> 220 mmol/L (2.5 mg/dL)
* Thrombocytopenia or coagulopathy
* Contraindication to heparin
* Pregnancy
* Acute illness or active systemic infection
* Other disease process likely to limit survival to less than 12 months
* Significant medical problem that, in the opinion of the principal investigator, would preclude enrollment into the study
* Participation in another investigational study
* Unwillingness to participate or lack of availability for follow-up
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active comparator.

Patients who completed 178-CL-046 (NCT00689104) or 178-CL-047 (NCT00662909) or new patients could be enrolled in this study if eligible.

Eligibility Criteria:
Inclusion Criteria:

* Patient is willing and able to complete the micturition diary and questionnaires correctly
* Patient has symptoms of overactive bladder for ≥ 3 months
* Patient experiences frequency of micturition on average ≥ 8 times per 24-hour period during the 3-day micturition diary period
* Patient must experience at least 3 episodes of urgency (grade 3 or 4) with or without incontinence, during the 3-day micturition diary period

Exclusion Criteria:

* Patient is breastfeeding, pregnant, intends to become pregnant during the study, or of childbearing potential, sexually active and not practicing a highly reliable method of birth control
* Patient has significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor
* Patient has an indwelling catheter or practices intermittent self-catheterization
* Patient has diabetic neuropathy
* Patient has evidence of a symptomatic urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs
* Patient receives non-drug treatment including electro-stimulation therapy
* Patient has severe hypertension
* Patient has a known or suspected hypersensitivity to tolterodine, other anticholinergics, YM178, other beta-adrenoreceptor (ß-AR) agonists, or lactose or any of the other inactive ingredients
* Patient has been treated with any investigational drug or device within 30 days (90 days in the UK for all clinical studies except 178-CL-046)
* Patient had an average total daily urine volume \> 3000 mL as recorded in the 3-day micturition diary period
* Patient has serum creatinine \>150 umol/L, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 2x upper limit of normal range (ULN), or gamma-glutamyl transpeptidase (γ-GT) \> 3x ULN
* Patient has a clinically significant abnormal electrocardiogram (ECG)
Evaluation of Antibacterial Effect of Allium Sativum, Calcium Hydroxide and Their Combination in Infected Mature Teeth

This study was to evaluate and compare garlic extract antibacterial effect when used as an intra-canal medicament in infected mature anterior teeth with calcium hydroxide and a mixture of calcium hydroxide and garlic, using real time PCR analysis.

Sixty-six permanent mature necrotic incisors associated with apical periodontitis in male children were selected. Teeth were randomly divided into three groups (n=22) according to intra canal medications used; group I: Ca OH2, group II: garlic extract and group III: mixture of Ca OH2 and garlic extract. After access preparation, four microbiological samples (S) were taken using sterile absorbent paper points as follows; (S1): were taken before canal instrumentation and irrigation. (S2): after cleaning and shaping, Then, the third samples (S3) and forth samples (S4) were taken after placement of the tested intracanal medications into the corresponding canals, for 7 and 14 days respectively. Total DNA was extracted from microbiological samples and relative quantitive real time PCR reactions were done to quantify the relative gene expression levels (FC) for Streptococcus and Enterococcus faecalis species. Data was statistically analyzed using Kruskal-Wallis and Freidman's tests, followed by Mann-Whitney and Wilcoxon singed rank tests at significance level p ≤ 0.05.

Eligibility Criteria:
Inclusion Criteria:

1. Cooperative male children with age ranging from 10 to 13 years.
2. All patients should have pulp necrosis with apical periodontitis in one or more upper incisor(s).
3. Teeth included in the study were preliminarily evaluated by preoperative periapical radiographs and should have: single canal (type I vertucci's classification) with closed apices, periapical lesions of endodontic origin with a diameter ranging from 2 to 5 mm without any previous RCT procedure.

Exclusion Criteria:

1. immune-compromised patient or patient with complicating systemic disease.
2. Patients received antibiotic therapy within the previous 3 months.
3. Tooth having gross carious lesions, fractures or cracks involving the periodontium (un-restorable tooth).
4. Tooth with root canal calcifications or resorption

6- Tooth with periodontal pockets of more than 4 mm depth, with or without endo-perio communication either concomitant or combined.
Prevention and Treatment of Perioperative Lung Injury in Elderly Patients

This study aims to verify the prediction model of postoperative pulmonary complications by collecting clinical information on elderly patients. In addition, the incidence of postoperative pulmonary complications in elderly patients before and after using the prediction model was compared.

More than 300 million major operations are performed worldwide each year, and older patients account for about a third of elective operations. Compared with young people, the elderly are more prone to postoperative complications due to age-related degeneration of the physiological functions of various organs and tissues. Postoperative pulmonary complications, including pneumonia, atelectasis, and respiratory failure, are common. Even mild pulmonary complications can lead to the prolonged hospital stay and increased postoperative mortality.

Although there have been many studies on postoperative lung complications, there have been few studies on elderly patients. In our country, the real incidence data of elderly patients after a perioperative period of pulmonary complications, the lack of effective prevention, intervention measures, and targeted prevention and treatment technology, these reasons lead to the clinical diagnosis and treatment of elderly patients after a perioperative period of pulmonary complications are very difficult. Therefore, the research team intends to verify the established prediction model of postoperative pulmonary complications and compare the incidence of postoperative pulmonary complications in elderly patients before and after using the prediction model.

Eligibility Criteria:
Inclusion Criteria:

1. Age 65 years or older
2. receiving invasive ventilation during general anesthesia for surgery

Exclusion Criteria:

1. preoperative mechanical ventilation
2. procedures related to a previous surgical complication
3. a second operation after surgery within one week
4. organ transplantation
5. discharged within 24 hours after surgery
Vestibular Rehabilitation and Otolith Dysfunction

Recent studies suggest that otolith dysfunction is a common finding in individuals with a history of head trauma/blast exposure and/or noise-induced hearing loss. Therefore, otolith dysfunction may be a significant health concern for the Veteran population, and determining optimal intervention strategies for otolith dysfunction is important for VA healthcare. The purpose of this project is to identify optimum stimulus parameters of a novel treatment, off-axis rotation (centrifugation) for otolith dysfunction, in healthy participants.

The primary function of the vestibular (inner ear balance) system is to maintain gaze and postural stability. The vestibular system is comprised of two types of sensory organs (semicircular canals and otolith organs) each with unique contributions to balance.

Vestibular Rehabilitation (VR) is the treatment of choice for patients experiencing dizziness, imbalance, and mobility impairments related to vestibular dysfunction. VR typically includes gaze stability exercises, gait and balance training, and general conditioning. Gaze stability exercises were developed based on the concepts of adaptation and substitution with the goal of improving gaze stability by facilitating vestibular compensation of the semicircular canal-mediated vestibulo-ocular reflex (VOR).

Many factors that might influence recovery, such as the involvement of different vestibular sensory organs (semicircular canals versus otolith organs) have not been examined to determine their impact on recovery. Most studies examining the effectiveness of VR have used only tests of VOR function (caloric and rotational tests) that measure horizontal semicircular canal to determine vestibular loss. Thus, little is known about interventions to facilitate vestibular compensation of the otolith organs.

Recent studies have demonstrated adaptation following otolith organ stimulation using centrifugation (or linear acceleration), but there is no data regarding optimum stimulus parameters. The concept of using centrifugation for otolith adaptation may be similar to using gaze stability exercises for VOR adaptation. Healthy control subjects (n = 5 per experiment) will participate in three separate experiments to determine: (1) the optimum off-axis distance of the rotary chair, (2) the optimum duration of off-axis rotation (OAR), and (3) the optimum OAR stimulation/training schedule.

Eligibility Criteria:
Inclusion Criteria:

* At least 18 years of age
* Documented balance or mobility problems, or healthy control without imbalance
* Otolith dysfunction or healthy control without vestibular dysfunction

Exclusion Criteria:

* Progressive neurological disorders and central vestibular abnormalities
* Benign paroxysmal positional vertigo
* Superior semicircular canal dehiscence
* Middle-ear pathology with conductive hearing loss
* Lower extremity joint replacement
* Cognitive impairment (Mini Mental Status Exam \< 24/30)
* Severe depression (geriatric depression scale 10)
* Severe anxiety (geriatric anxiety inventory 11/30)
* Best-corrected visual acuity worse than 20/40 in the better eye